Tosk discovers and develops new drugs to improve outcomes for cancer patients by reducing adverse side effects of chemotherapeutic drugs.
Tosk develops new drugs to improve outcomes for cancer patients by reducing the undesirable side effects of cancer chemotherapy. Tosk has developed two important side-effect-reducing agents, TK-90 for mucositis and TK-39 for cardiotoxicity. The Company has initiated human clinical studies for TK-90 and plans clinical studies for TK-39 in 2015. A product for pulmonary fibrosis is under development using Tosk's patented drug discovery platform.